UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

The Lancet (British edition), 2011-12, Vol.378 (9808), p.2005-2012

2011

Volltextzugriff (PDF)

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

Multiple sclerosis, 2022-09, Vol.28 (10), p.1576-1590

2022

Volltextzugriff (PDF)

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience

Cancer research (Chicago, Ill.), 2013-03, Vol.73 (5), p.1449-1453

2013

Volltextzugriff (PDF)

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks

Trials, 2021-06, Vol.22 (1), p.420-420, Article 420

2021

Volltextzugriff (PDF)

Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting

Ophthalmology science (Online), 2024-01, Vol.4 (1), p.100361-100361, Article 100361

2024

Volltextzugriff (PDF)

Comparative Safety Assessment of Ofatumumab using Data from ASCLEPIOS I/II versus a Historical Propensity-adjusted Placebo Arm (2221)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Pregnancy outcomes in patients with MS following exposure to ofatumumab: Updated results (Novartis safety database)

Journal of neurology, neurosurgery and psychiatry, 2023-11, Vol.94 (Suppl 1), p.A66-A67

2023

Volltextzugriff (PDF)

Survival analysis for AdVerse events with VarYing follow‐up times (SAVVY): Rationale and statistical concept of a meta‐analytic study

Biometrical journal, 2021-03, Vol.63 (3), p.650-670

2021

Volltextzugriff (PDF)

Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis (P9-6.007)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Pregnancy Outcomes in Patients With MS Following Exposure to Ofatumumab: Updated Results From the Novartis Safety Database (P9-3.014)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis

Biometrical journal, 2020-05, Vol.62 (3), p.658-669

2020

Volltextzugriff (PDF)

Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis (RMS) Patients from the Phase 3 ASCLEPIOS I and II Trials (1300)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Improving data collection in pregnancy safety studies: Towards standardization of data elements in pregnancy reports from public and private partners (ConcePTION)

Neurotoxicology and teratology, 2023-07, Vol.98, p.107210, Article 107210

2023

Volltextzugriff (PDF)

Comparison of Adverse Event Risks in Randomized Controlled Trials with Varying Follow-Up Times and Competing Events: Results from an Empirical Study

Statistics in biopharmaceutical research, 2023-10, Vol.ahead-of-print (ahead-of-print), p.1-14

2023

Volltextzugriff (PDF)

Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2012-10, Vol.7 (10), p.1594-1601

2012

Volltextzugriff (PDF)

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS -mutant cutaneous melanoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9500-9500

2016

Volltextzugriff (PDF)

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Investigational new drugs, 2014-02, Vol.32 (1), p.123-134

2014

Volltextzugriff (PDF)

Cumulative Efficacy and Safety of 5-Year Deferasirox (Exjade®) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial

Blood, 2008-11, Vol.112 (11), p.5413-5413

2008

Volltextzugriff (PDF)

Das Geheime Staatsarchiv Preußischer Kulturbesitz

Geheimes Staatsarchiv Preußischer Kulturbesitz, Teil II, 2000, Vol.5, p.XV-XVI

Originally published 2000, 2000

Volltextzugriff (PDF)

Hauptabteilung: Provinz Sachsen

Geheimes Staatsarchiv Preußischer Kulturbesitz, Teil II, 2000, Vol.5, p.385-386

Originally published 2000, 2000

Volltextzugriff (PDF)

Hauptabteilung: Königreich Westphalen

Geheimes Staatsarchiv Preußischer Kulturbesitz, Teil II, 2000, Vol.5, p.323-326

Originally published 2000, 2000

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(41)

Publikationsform

Buchkapitel
(25)
Artikel
(22)

Sprache

Deutsch
(25)
Englisch
(22)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Clinical Trials
(7)
Humans
(6)
Adverse Events
(5)
Female
(5)
Patients
(5)
Adult
(4)
Aged
(4)
Everolimus
(4)
Male
(4)
Middle Aged
(4)
Oncology
(4)
Sirolimus - Analogs & Derivatives
(4)
Tumors
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Biological And Medical Sciences
(3)
Drug Safety
(3)
Mathematical & Computational Biology
(3)
Mathematics
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks

Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting

Comparative Safety Assessment of Ofatumumab using Data from ASCLEPIOS I/II versus a Historical Propensity-adjusted Placebo Arm (2221)

Pregnancy outcomes in patients with MS following exposure to ofatumumab: Updated results (Novartis safety database)

Survival analysis for AdVerse events with VarYing follow‐up times (SAVVY): Rationale and statistical concept of a meta‐analytic study

Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis (P9-6.007)

Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010)

Pregnancy Outcomes in Patients With MS Following Exposure to Ofatumumab: Updated Results From the Novartis Safety Database (P9-3.014)

Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis

Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project

Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis (RMS) Patients from the Phase 3 ASCLEPIOS I and II Trials (1300)

Improving data collection in pregnancy safety studies: Towards standardization of data elements in pregnancy reports from public and private partners (ConcePTION)

Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project

Comparison of Adverse Event Risks in Randomized Controlled Trials with Varying Follow-Up Times and Competing Events: Results from an Empirical Study

Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS -mutant cutaneous melanoma

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Cumulative Efficacy and Safety of 5-Year Deferasirox (Exjade®) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial

Das Geheime Staatsarchiv Preußischer Kulturbesitz

Hauptabteilung: Provinz Sachsen

Hauptabteilung: Königreich Westphalen

Suchergebnisse filtern